CAS Number: 942195-55-3
Chemical Formula: C₂₀H₁₉F₂N₃O₃
적응증: 프로톤펌프억제제(PPI)의 대안으로 자리매김한 칼륨경쟁적 위산분비차단제(P-CAB)를 통한 산 관련 위장질환 치료
IUPAC Name: 7-[[(4S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl]oxy]-N,N,2-trimethyl-3H-benzimidazole-5-carboxamide
EC Number:
Molecular Weight: 387.4
제형: 전형적인 P-CAB 제형에 부합하는 1일 1회 복용 경구정으로 제형화
규제 승인 상태: 한국에서 3상 임상개발이 완료되었으며 국제적으로 추가 3상 연구 진행

기타 정보

추가 설명:

Tegoprazan is a novel, patented potassium-competitive acid blocker (P-CAB) that addresses limitations found in traditional proton pump inhibitors (PPIs) and rival P-CABs. Its advantages have been shown through Phase 3 trials in Korea and a Phase 1 trial in the US, leading to MFDS approval in 2019 across four indications: erosive reflux disease (ERD), non-erosive gastroesophageal reflux disease (NERD), gastric ulcer (GU), and Helicobacter pylori eradication. Beyond South Korea, it has gained approval in China, Mongolia, and the Philippines, among the 34 countries where HK inno.N has out-licensed it, and the company is actively seeking partners to develop Tegoprazan in unpartnered territories. Contact Ga-Young Lee (BD) at [email protected] for details.